Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Celera's genotyping system software receives 510(k) clearance

Celera : 21 July, 2008  (New Product)
Celera has received marketing clearance from the US Food and Drug Administration for its 510(k) submission of the ViroSeq HIV-1 Genotyping System Software v2.8.
The ViroSeq HIV-1 Genotyping System is designed to detect mutations in the HIV-1 viral genome that confer drug resistance, and as such, is used as an aid in monitoring and treating HIV-1 infections. Features of the updated software include:

- The addition in the resistance algorithm of two new drugs, Intelence (etravirine) and Prezista (darunavir) from Tibotec Therapeutics, a division of Ortho Biotech Products;

- An update of the resistance algorithm for all currently available protease and reverse transcriptase inhibitors; and,

- Support for the software on Intel-dual processor computers.

“The ViroSeq HIV-1 Genotyping System has become a standardised tool for physicians seeking the best course of drug treatment for HIV-1 infected individuals through monitoring of viral resistance,” said Michael Zoccoli, PhD, general manager of Celera’s Products business. “To ensure better management of HIV-1 infected patients, it is critical that we update our ViroSeq drug resistance algorithm to keep pace with new therapeutic interventions that optimize treatment of this life threatening disease.”

The efficacy of HIV-1 drug therapy is modulated by the mutation rate of the HIV-1 virus during drug treatment, which can lead to drug resistance and consequent therapeutic failure among individuals. Studies have found that a significant number of drug treated patients show signs of resistance to one or more drugs typically used to treat HIV. The rate of drug resistance among new cases is also increasing. Up to 15 percent of drug naive individuals newly diagnosed with HIV were infected with a strain that was already resistant to at least one antiretroviral drug.

Genotyping is a sequencing-based testing method that is routinely used by laboratories and clinicians throughout the world to determine the genetic composition of the HIV-1 virus. The ViroSeq System consists of an automated DNA sequencing platform, reagents and dedicated software used to genotype strains of the HIV-1 virus that infect the patient. The system targets specific regions of the viral genome that can develop drug-resistant mutations. ViroSeq’s high throughput processing provides an integrated system from sample preparation to the final interpretive resistance report to aid the physician in drug treatment decisions.

The ViroSeq HIV-1 Genotyping System is manufactured by Celera and is distributed by Abbott Laboratories.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo